证券代码：300562 证券简称：乐心医疗 公告编号：2023-072 广东乐心医疗电子股份有限公司 乐心医疗 2023 年公告 3、会议召集及召开程序符合《中华人民共和国公司法》等相关法律法规和 《公司章程》有关规定，表决形成的决议合法、有效。 二、董事会会议审议情况 本次会议以书面记名投票方式进行表决，经与会董事们认真审议通过以下决 议： 1、审议通过《关于<公司 2023 年半年度报告全文>及摘要的议案》 经审议，公司董事会认为：公司 2023 年半年度报告全文及其摘要所载资料 内容真实、准确、完整，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、广东乐心医疗电子股份有限公司（以下简称"乐心医疗"或"公司"） 第四届董事会第九次会议于 2023 年 08 月 01 日以电子邮件、电话、专人送达等 方式通知全体董事，会议于 2023 年 08 月 11 日以现场结合线上的方式召开。 2、本次会议 ...

海通证券股份有限公司 关于广东乐心医疗电子股份有限公司 购买控股子公司少数股权暨关联交易的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为广东 乐心医疗电子股份有限公司（以下简称"乐心医疗"或"公司"）2021 年向特定 对象发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券 交易所创业板股票上市规则（2023 年修订）》《深圳证券交易所上市公司自律监 管指引第 13 号——保荐业务》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》等有关法律法规和规范性文件的要求，对乐心医疗 购买控股子公司少数股权暨关联交易事项进行核查，具体情况如下： 一、本次关联交易概述 （一）本次关联交易基本情况 为进一步资源整合，更好地优化资源配置、聚焦远程健康领域，公司拟购买 控股子公司乐心医疗远程科技（珠海）有限公司（以下简称"乐心远程"）少数 股东合计 49.00%的股权，本次完成后乐心远程将变成公司的全资子公司，本次 交易不会导致公司合并范围变更。 （二）关联关系说明 乐心远程少数股东之一潘农菲先生为公司董事以及过去十二个月内离职的 高级管理人员，其持有乐心远 ...

2023 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 广东乐心医疗电子股份有限公司 2023 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 非经营性资金占用 资金占用方名称 占用方与上市公 司的关联关系 上市公司核算 的会计科目 2023 年期 初占用资金 余额 2023 年 1-6 月占 累计发生金额 （不含利息） 2023 年 1-6 月占 用资金的利息 （如有） 2023 年 1-6 月 偿还累计发生 金额 2023 年 6 月 30 日占用资金余 额 占用形成原因 占用性质 控股股东、实际控 制人及其附属企业 非经营性占用 非经营性占用 小计 - - - - 前控股股东、实际 控制人及其附属企 业 非经营性占用 非经营性占用 小计 - - - - 其他关联方及附属 企业 非经营性占用 小计 总计 - - - - 其它关联资金往来 资金往来方名称 往来方与上市公 司的关联关系 上市公司核算 的会计科目 2023 年期 初占用资金 余额 2023 年 1-6 月占 累计发生金额 （不含利息） 2023 年 1-6 月占 用资金的利息 （如有） 2023 年 1-6 ...

乐心医疗 2023 年公告 关于监事会对2023年限制性股票激励计划激励对象名单的审核意见 及公示情况的说明 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）于 2023 年 07 月 26 日召开了第四届董事会第八次会议、第四届监事会第七次会议，审议通过了《关 于<2023 年限制性股票激励计划（草案）>及其摘要的议案》、《关于<2023 年限制 性股票激励计划实施考核管理办法>的议案》以及《关于核实<2023 年限制性股 票激励计划激励对象名单>的议案》等议案，具体内容详见公司于 2023 年 07 月 27 日披露在巨潮咨询网（www.cninfo.com.cn）的相关内容。 根据《上市公司股权激励管理办法》、《深圳证券交易所创业板上市公司自律 监管指南第 1 号——业务办理》、《深圳证券交易所创业板股票上市规则》等相关 规定，公司监事会对 2023 年限制性股票激励计划（以下简称"本激励计划"） 的激励名单和公示情况进行了核查，相关意见如下： 一、监事会对本激励计划激励名单的审核意见 公司监事会对本激励计 ...

证券代码：300562 证券简称：乐心医疗 广东乐心医疗电子股份有限公司投资者关系活动记录表 编号：2023-001 投资者关系 活动类别 □ 特定对象调研 □ 分析师会议 □ 媒体采访 ■ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 参与单位名 称及人员 参与"乐心医疗 2022 年度网上业绩说明会"的投资者 时间 2023 年 05 月 08 日（星期一）下午 15:00-17:00 地点 网上业绩说明会 上市公司接 待人员姓名 董事长、总经理：潘伟潮先生 独立董事：周康先生 董事会秘书：钟玲女士 财务总监：黄林香女士 保荐代表人：桑继春女士 投资者关系 活动主要内 容介绍 本次年度业绩说明会采用网络远程的方式举行，主要就以下内容进行交 流： 一、2022 年度公司情况简介 乐心医疗深耕智能健康领域多年，聚焦远程健康垂直领域，锚定医疗级 远程健康监测设备及服务提供商的战略定位，依托自身在智能医疗健康、智 能可穿戴等领域产品创新研发、产品品质和应用技术等方面的独特优势，将 健康 IoT、大数据与医疗深度融合，形成"健康 IoT+数字健康服务"双轮驱 动的主业布局。 2022 年，公司坚 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 162.61 million, a decrease of 37.55% compared to CNY 260.37 million in the same period last year[7]. - The net profit attributable to shareholders was a loss of CNY 12.10 million, a decline of 1,040.75% from a profit of CNY 1.29 million in the previous year[7]. - The net cash flow from operating activities was negative CNY 13.32 million, a decrease of 130.32% compared to CNY 43.93 million in the same period last year[7]. - Total operating revenue for Q1 2023 was CNY 162.61 million, a decrease of 37.5% compared to CNY 260.37 million in the same period last year[25]. - Net profit for Q1 2023 was a loss of CNY 12.33 million, compared to a profit of CNY 1.11 million in Q1 2022, representing a significant decline[26]. - Cash received from sales of goods and services was CNY 209.41 million, a decrease of 56.0% from CNY 475.52 million in Q1 2022[28]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1.45 billion, down 6.29% from CNY 1.55 billion at the end of the previous year[7]. - Total current assets decreased from CNY 985,129,961.65 at the beginning of the year to CNY 882,135,881.40 at the end of the period, a reduction of approximately 10.5%[21]. - Total liabilities decreased to CNY 465.19 million from CNY 548.46 million, reflecting a reduction of 15.1%[23]. - The total equity attributable to shareholders of the parent company was CNY 998.32 million, down from CNY 1,012.06 million, a decline of 1.4%[23]. - Total current liabilities decreased from CNY 501,323,424.25 to CNY 419,449,687.58, a decrease of approximately 16.3%[22]. Cash Flow - The company reported a net cash outflow from operating activities of CNY 13.32 million, compared to a net inflow of CNY 43.93 million in the previous year[28]. - The net cash flow from investment activities was -230,113,325.71 CNY, compared to a positive cash flow of 47,498,024.77 CNY in the previous year[29]. - Total cash and cash equivalents at the end of the period amounted to 298,020,147.54 CNY, down from 422,592,937.24 CNY at the end of the previous year[29]. - The company experienced a decrease in cash and cash equivalents by 246,910,346.19 CNY during the quarter[29]. - The initial cash and cash equivalents balance was 544,930,493.73 CNY, reflecting a significant liquidity position at the start of the quarter[29]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 23,642[17]. - The largest shareholder, Pan Weichao, holds 33.57% of shares, totaling 72,066,874 shares, with 55,668,055 shares pledged[17]. - The number of restricted shares held by executives decreased from 61,110,328 to 56,326,453 after unlocking 4,783,875 shares[19]. Operational Focus and Strategy - The company is focusing on optimizing customer and product structure, which has impacted revenue scale during the reporting period[7]. - The company plans to enhance its product competitiveness through advanced technology and expand into emerging markets and diverse sales channels[8]. - The company aims to improve its production and operational situation through cost reduction and efficiency enhancement measures[8]. - The company has not disclosed any new product developments or market expansion strategies in the current report[18]. Financial Expenses and Investments - The company experienced a significant increase in trading financial assets, rising by 354.49% to CNY 270.61 million due to the use of idle funds for bank wealth management products[12]. - The company reported a substantial increase in financial expenses, up 411% to CNY 3.49 million, primarily due to foreign exchange losses from USD-denominated assets[13]. - The company recorded an investment loss of CNY 320.20 thousand, contrasting with a profit of CNY 1.45 million in the previous year[26]. - The company reported a cash inflow from investment activities of 58,672,325.83 CNY, compared to 102,009,190.14 CNY in the previous year[29]. - The company’s cash outflow related to investment activities was significantly higher at 288,785,651.54 CNY compared to the previous year's 54,511,165.37 CNY[29]. Research and Development - Research and development expenses for Q1 2023 were CNY 26.55 million, a decrease of 19.5% from CNY 33.01 million in the same period last year[25]. Audit and Reliability - The report for the first quarter was not audited, indicating potential limitations in the reliability of the financial data presented[30].

广东乐心医疗电子股份有限公司2022年年度报告全文 广东乐心医疗电子股份有限公司 2022 年年度报告 2023-023 【披露时间】 ...

乐心医疗 2023 年公告 关于举行 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"或"乐心医疗"）《2022 年年度报告》及其摘要已于 2023 年 04 月 28 日刊登于中国证监会指定的创业板 信息披露网站，为了更好地与广大投资者进行交流，使投资者能够进一步了解公 司经营业绩、发展战略等情况，公司将举行 2022 年度网上业绩说明会。 一、会议召开日期和时间 2023 年 05 月 08 日（星期一）下午 15:00-17:00 证券代码：300562 证券简称：乐心医疗 公告编号：2023-037 广东乐心医疗电子股份有限公司 （二）"约调研"平台参与方式： 1、参与方式一：在微信中搜索小程序"乐心医疗投资者关系"参与交流； 乐心医疗 2023 年公告 2、参与方式二：微信扫一扫以下二维码参与交流： 二、会议召开方式及地点 本次业绩说明会将在同花顺路演平台和"约调研"平台采用网络远程的方式 举行。 三、公司出席人员 参加此次网上业绩说明会的公司人员有：董事长潘伟潮先生、 ...

Financial Performance - The company's revenue for the first half of 2022 was CNY 541.05 million, a decrease of 32.23% compared to the same period last year[32]. - The net profit attributable to shareholders for the same period was CNY 6.87 million, down 66.48% year-on-year[32]. - The net cash flow from operating activities improved significantly, reaching CNY -15.06 million, an 85.61% increase compared to the previous year[32]. - Research and development expenses totaled CNY 69.17 million, accounting for 12.78% of revenue, which is a 14.32% increase year-on-year[33]. - The company's gross profit margin increased by 5.1% compared to the previous year, indicating improved cost structure management[33]. - Total assets at the end of the reporting period were CNY 1.54 billion, a decrease of 14.15% from the end of the previous year[32]. - The net assets attributable to shareholders were CNY 1.07 billion, reflecting a slight increase of 1.10% compared to the previous year[32]. - Basic earnings per share decreased by 70.00% to CNY 0.03 per share[32]. - The company's operating revenue for the current period was ¥541,048,823.31, a decrease of 32.23% compared to the same period last year, primarily due to strategic adjustments in response to global economic changes[104]. - Operating costs decreased by 36.46% to ¥416,673,585.77, mainly attributed to the decline in operating revenue[104]. - The company reported a significant increase in other income by 144.28% to ¥7,181,801.61, primarily from government subsidies[109]. Strategic Focus and Goals - The company is focusing on enhancing its management capabilities to match its rapid growth and strategic goals in becoming a world-class health IoT and digital health service provider[8]. - The strategic focus remains on becoming a world-class provider of health IoT and digital health services[33]. - The company aims to enhance its global competitiveness by focusing on remote healthcare, home healthcare, and chronic disease management[33]. - The company aims to strengthen its market presence and increase product market share through improved product value and competitive capabilities[9]. - The company is committed to continuous innovation and development of new technologies in the healthcare sector[84]. - The company plans to strengthen its product value and competitive capabilities to improve market share and overall profitability in overseas markets[133]. - The company aims to enhance user engagement and market share through big data analysis and AI technology in health management[45]. Research and Development - The company is committed to increasing R&D investment to improve product technology and develop more user-friendly and differentiated products[11]. - The company emphasizes independent research and development, ensuring product quality and intellectual property rights[45]. - The company has achieved self-research and production capabilities in core components such as sensors and algorithms, enhancing its innovation capacity in biological signal sensing[91]. - The company has built a multi-device collaborative computing framework with its own IoT operating system, focusing on data-driven and open platform strategies[91]. - The company has completed one new patent application related to remote health management technology and one utility model patent for voice-interactive scales[73]. - The company holds a total of 545 patents, including 95 invention patents, 209 utility model patents, and 241 design patents[94]. Market Conditions and Risks - The company faces significant risks from international market fluctuations, particularly in developed regions like Europe, the US, Japan, and South Korea, where export revenue constitutes a large portion of total income[9]. - Rising costs of raw materials and labor pose a challenge to the company's cost control, which could negatively impact profitability[12]. - The health IoT and remote health management market in China is projected to exceed 4 trillion yuan by 2030, driven by population growth and increased health awareness[56]. - The global remote health management market is expected to reach 185.7 billion USD by 2026, indicating a strong growth trajectory[56]. - The aging population is driving the demand for chronic disease management, necessitating the development of comprehensive health management systems[64]. Product Development and Innovation - The company has developed a digital sports management system for schools, utilizing wearable devices to monitor students' health metrics[50]. - The company has established a digital health management solution that integrates IoT and digital health services, covering multiple industries such as insurance and education[47]. - The health IoT product line includes a comprehensive range of monitoring devices, with several products certified as Class II medical devices[43]. - The company has successfully launched a remote blood pressure management system, which includes a health management system for real-time data upload and visualization, now in mass production[71]. - Wearable devices have been developed to monitor health metrics such as heart rate and activity levels, with a focus on improving lifestyle habits, and the system design has been completed for mass production in 2022[71]. - The company has developed a new generation of ECG smart watches, integrating multiple functions and establishing a robust hardware platform for future wearable products[73]. Financial Management and Investments - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[14]. - The company has proposed to delay the investment projects related to the production base and R&D center due to not meeting the planned progress[121]. - The company has not allocated any funds to the projects that have not reached the planned progress or expected benefits[121]. - The company has invested a total of 190 million yuan in bank financial products using idle fundraising for cash management, all of which have been redeemed by the end of the reporting period[125]. - The total amount of raised funds was RMB 59.46 million, with RMB 4.01 million invested during the reporting period and a cumulative investment of RMB 31.45 million[120]. Corporate Governance and Compliance - The company has experienced changes in its board of directors, with several members resigning and new members being elected during the reporting period[143]. - The semi-annual financial report was not audited[171]. - The company has no outstanding guarantees to external parties, and no guarantees were approved during the reporting period[189]. - The company has no significant penalties or rectifications reported during the period[175]. - The company actively participates in social welfare activities, including support for disabled employees[161]. Community Engagement and Sustainability - The company actively promotes energy conservation and emission reduction, aligning with national "dual carbon" policies[156]. - The company provided various types of employment positions to alleviate employment pressure during the global pandemic and unstable environment[160]. - The company supported local Red Cross initiatives and organized employee participation in blood donation activities, contributing to community welfare[161]. - The company is committed to sustainable development and promoting energy conservation among employees[162].

Financial Performance - The company's revenue for Q1 2022 was CNY 260,374,797.52, a decrease of 28.79% compared to CNY 365,624,197.46 in the same period last year[5] - Net profit attributable to shareholders was CNY 1,286,018.55, down 90.09% from CNY 12,978,298.10 year-on-year[5] - Total operating revenue for Q1 2022 was CNY 260.37 million, a decrease of 28.7% compared to CNY 365.62 million in the same period last year[25] - Total operating costs for Q1 2022 were CNY 268.60 million, down 25.2% from CNY 358.98 million year-over-year[25] - Net profit for Q1 2022 was CNY 1.11 million, a significant decline of 88.6% from CNY 9.71 million in Q1 2021[26] - The company reported a total comprehensive income of CNY 1.07 million for Q1 2022, compared to CNY 9.65 million in the same quarter last year[27] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.01, down from CNY 0.07 in Q1 2021[27] Cash Flow - The net cash flow from operating activities increased significantly by 939.45%, reaching CNY 43,925,115.81, compared to a negative cash flow of CNY -5,232,595.94 in the previous year[14] - The net cash flow from operating activities for Q1 2022 was ¥43,925,115.81, a significant improvement compared to a net outflow of ¥5,232,595.94 in Q1 2021[30] - Total cash inflow from investment activities was ¥102,009,190.14, compared to ¥39,257,480.00 in the same period last year, resulting in a net cash flow from investment activities of ¥47,498,024.77, up from ¥14,096,783.38[30] - The net cash flow from financing activities was ¥2,266,206.31, a decrease from ¥370,393,135.70 in Q1 2021, primarily due to lower cash inflow from investment[31] - The total cash outflow for operating activities was ¥461,501,292.31, compared to ¥511,360,274.64 in Q1 2021, indicating improved cash management[30] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,636,175,441.87, down 8.82% from CNY 1,794,485,114.25 at the end of the previous year[5] - Total current liabilities decreased from ¥711,349,889.91 to ¥547,797,910.28, a reduction of about 22.9%[22] - Total liabilities amounted to CNY 581.85 million, a decrease from CNY 747.10 million year-over-year[26] - Total equity attributable to shareholders of the parent company was CNY 1,061.96 million, up from CNY 1,054.84 million in the previous year[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 22,530[16] - The largest shareholder, Pan Weichao, holds 37.54% of shares, totaling 80,602,574 shares, with 34,530,000 shares pledged[16] - The total number of shares held by the top ten unrestricted shareholders amounts to 37,150,000 shares[17] - The company has a total of 67,999,506 shares under lock-up due to executive restrictions[19] Government Support and Subsidies - The company received government subsidies amounting to CNY 1,275,779.04, contributing to other income of CNY 1,362,665.59, which increased by 319.78% year-on-year[13] Research and Development - Research and development expenses increased to CNY 33.01 million, up 14.0% from CNY 28.98 million in the previous year[26] Inventory and Accounts Receivable - The company experienced a 41.78% decrease in accounts receivable, totaling CNY 234,069,179.69, due to improved customer payment management[11] - Accounts receivable decreased significantly from ¥402,020,098.66 to ¥234,069,179.69, a reduction of about 41.8%[21] - The company reported a total of ¥200,454,047.96 in inventory at the end of the reporting period, down from ¥208,807,972.42[21] Production Costs and Profit Margins - The net profit margin was significantly impacted by increased production costs due to global supply chain issues and a strategic focus on core business areas[6]